Literature DB >> 20122733

Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.

Mary T Litzinger1, Kenneth A Foon, Kwong-Yok Tsang, Jeffrey Schlom, Claudia Palena.   

Abstract

Adenoviral transduction with CD40L and poxviral transduction with B7-1, ICAM-1, and LFA-3 (TRICOM) have been used to enhance the antigen-presenting capacity of chronic lymphocytic leukemia (CLL) cells. This study compares the same vector (modified vaccinia virus strain Ankara (MVA)) encoding CD40L or TRICOM for its ability to enhance the immunogenicity of CLL cells. CLL cells from some patients showed differential responses to each vector in terms of induction of autologous T-cell responses. This study supports the rationale for the use of CLL cells modified ex vivo with pre-specified recombinant MVA vectors as a whole tumor-cell vaccine for immunotherapy in CLL patients. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20122733      PMCID： PMC2891581          DOI： 10.1016/j.leukres.2009.12.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  37 in total

1.  Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.

Authors:  J W Hodge; D W Grosenbach; A N Rad; M Giuliano; H Sabzevari; J Schlom
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

2.  Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.

Authors:  J C Ramírez; M M Gherardi; M Esteban
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.

Authors:  Javier Briones; John M Timmerman; Dennis L Panicalli; Ronald Levy
Journal:  J Natl Cancer Inst       Date:  2003-04-02       Impact factor: 13.506

4.  CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Authors:  W G Wierda; M J Cantwell; S J Woods; L Z Rassenti; C E Prussak; T J Kipps
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

5.  Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kappaB activation.

Authors:  K L Oie; D J Pickup
Journal:  Virology       Date:  2001-09-15       Impact factor: 3.616

6.  Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.

Authors:  S Takahashi; R F Rousseau; P Yotnda; Z Mei; G Dotti; D Rill; R Hurwitz; F Marini; M Andreeff; M K Brenner
Journal:  Hum Gene Ther       Date:  2001-04-10       Impact factor: 5.695

7.  Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia.

Authors:  M R Rezvany; M Jeddi-Tehrani; H Rabbani; N Lewin; J Avila-Cariño; A Osterborg; H Wigzell; H Mellstedt
Journal:  Br J Haematol       Date:  2000-11       Impact factor: 6.998

8.  Vaccination against pox diseases under immunosuppressive conditions.

Authors:  A Mayr; K Danner
Journal:  Dev Biol Stand       Date:  1978

9.  Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.

Authors:  James W Hodge; Jack Higgins; Jeffrey Schlom
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

10.  Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals.

Authors:  Antonio Cosma; Rashmi Nagaraj; Silja Bühler; Jorma Hinkula; Dirk H Busch; Gerd Sutter; Frank D Goebel; Volker Erfle
Journal:  Vaccine       Date:  2003-12-08       Impact factor: 3.641
View more
  2 in total

Review 1.  Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.

Authors:  Athalia R Pyzer; David E Avigan; Jacalyn Rosenblatt
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.

Authors:  Sruthi Ravindranathan; Khue G Nguyen; Samantha L Kurtz; Haven N Frazier; Sean G Smith; Bhanu Prasanth Koppolu; Narasimhan Rajaram; David A Zaharoff
Journal:  Breast Cancer Res       Date:  2018-10-22       Impact factor: 6.466
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.